Relyea Zuckerberg Hanson’s iShares Genomics Immunology and Healthcare ETF IDNA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q2
Sell
-6,400
Closed -$221K 145
2022
Q1
$221K Buy
+6,400
New +$226K 0.07% 144
2021
Q4
Sell
-6,800
Closed -$345K 148
2021
Q3
$345K Buy
+6,800
New +$354K 0.13% 108

Other funds holding IDNA

Relyea Zuckerberg Hanson's IDNA Position: Q2 2022 in Review

Relyea Zuckerberg Hanson sold out of iShares Genomics Immunology and Healthcare ETF (IDNA) in Q2 2022, closing a stake of 6,400 shares — an estimated $221K sold.

Relyea Zuckerberg Hanson first reported a position in IDNA in Q3 2021 and held it in 2 quarters. The position peaked at $345K in Q3 2021. 73 funds tracked by Wall St. Rank hold IDNA as of Q2 2022.

  • Relyea Zuckerberg Hanson reported no remaining iShares Genomics Immunology and Healthcare ETF position as of Q2 2022 after selling out during the quarter.
  • Relyea Zuckerberg Hanson sold 6,400 iShares Genomics Immunology and Healthcare ETF shares in Q2 2022, an estimated $221K.
  • Relyea Zuckerberg Hanson first reported a position in iShares Genomics Immunology and Healthcare ETF in Q3 2021 and held it in 2 quarters.
  • Relyea Zuckerberg Hanson's iShares Genomics Immunology and Healthcare ETF position peaked at $345K in Q3 2021.
  • 73 funds tracked by Wall St. Rank held iShares Genomics Immunology and Healthcare ETF as of Q2 2022.

Based on Relyea Zuckerberg Hanson's 13F filing for Q2 2022, filed 18 Jul 2022.